| Literature DB >> 29468051 |
Alison Nicholson1, Ingrid Tennant2, Livingston White3, Camille-Ann Thoms-Rodriguez1, Loraine Cook4, Stephen Johnson5, Tamara Thompson6, Jasper Barnett7, Lundie Richards7.
Abstract
Background: Antibiotic resistance (ABR) is a serious threat that requires coordinated global intervention to prevent its spread. There is limited data from the English-speaking Caribbean.Entities:
Keywords: Antibiotic; Attitudes; Knowledge; Practices; Prescribing; Resistance
Mesh:
Substances:
Year: 2018 PMID: 29468051 PMCID: PMC5815225 DOI: 10.1186/s13756-018-0315-3
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Physician Demographics
| Category | Frequency | Percent | |
|---|---|---|---|
| Gender | Male | 338 | 49% |
| Female | 348 | 51% | |
| Current Practice | Mainly hospital based | 387 | 60% |
| Mainly outpatient or clinic based | 158 | 25% | |
| An equal proportion of both | 97 | 15% | |
| Total | 642 | 100% | |
| Position | Intern/SHO | 118 | 17% |
| Intern/resident | 186 | 27% | |
| Senior/chief resident | 43 | 6% | |
| Consultant | 156 | 22% | |
| Private GP | 120 | 17% | |
| Specialist private practice | 38 | 5% | |
| Government clinic medical officer | 34 | 5% | |
| Total | 695 | 100% | |
| Postgraduate Training | Yes | 338 | 51% |
| No | 328 | 49% | |
| Total | 666 | 100% | |
| Specialty | Anaesthesia/intensive care | 56 | 17 |
| Internal medicine | 64 | 19 | |
| Surgical specialty | 102 | 31 | |
| Paediatrics | 27 | 8 | |
| Obstetrics and gynaecology | 24 | 7 | |
| Accident and emergency | 13 | 4 | |
| Family medicine | 42 | 13 | |
| Clinical microbiologist | 6 | 2 | |
| Years Post Registration | Total | 334 | 100% |
| 0–4 years | 218 | 32% | |
| 5–9 years | 130 | 19% | |
| 10–14 years | 87 | 13% | |
| 15–19 years | 61 | 9% | |
| >_ 20 years | 176 | 26% | |
| Total | 672 | 100% |
N.B. Total sample size for this study is 695. Differences in totals for each subsection occur because of missing values
Knowledge of Factors Contributing to Antibiotic Resistance
| Mean | SD | |
|---|---|---|
| Widespread use of antibiotics | 2.79 | .48 |
| Overuse of broad spectrum antibiotics | 2.74 | .55 |
| Inappropriate use of antibiotic therapy | 2.61 | .60 |
| Inappropriate initial choice of antibiotics | 2.58 | .62 |
| Lack of guidelines on antibiotic usage | 2.17 | .81 |
| Patients’ demand for antibiotics | 1.90 | .80 |
| Role of pharmaceutical companies in promoting the use of antibiotics | 1.75 | .79 |
| Inadequate hand washing | 1.47 | .95 |
| Use of antibiotics in the livestock industry | 1.41 | 1.03 |
Knowledge of Preventing or Containing Antibiotic Resistance
| Mean | SD | |
|---|---|---|
| Ongoing physician educational programmes | 2.67 | .659 |
| Access to timely lab reports | 2.67 | .674 |
| Development of national antibiotic guidelines | 2.63 | .684 |
| Access to microbiology consultations | 2.58 | .694 |
| Development of better diagnostic tests to differentiate bacterial from viral infection | 2.53 | .745 |
| Public educational programmes | 2.44 | .753 |
| Antibiotic restriction: requiring a countersignature by a consultant or microbiologist | 2.04 | .800 |
| Antibiotic cycling: switching routine use from one class to another at a regular intervals | 1.97 | .920 |
Knowledge of Inducing Antibiotic Resistance
| Mean | SD | |
|---|---|---|
| Amoxicillin-clavulanic acid | 1.51 | .70 |
| Ceftriaxone | 1.31 | .75 |
| Ciprofloxacin | 1.23 | .78 |
| Ceftazidime | 1.13 | .74 |
| Piperacillin-tazobactam | 1.01 | .70 |
| Meropenem/Imipenem | .98 | .70 |
| Amikacin | .94 | .65 |
(0 = don’t know, 1 = less likely, 2 = more likely)
Choices of Empiric Antibiotics
| Community acquired pneumonia | Hospital acquired pneumonia | Uncomplicated urinary tract infection | Overall | |
|---|---|---|---|---|
| Amoxicillin-clavulanic acid | 77% | 21% | 44% | 53% |
| Erythromycin | 38% | 11% | 3% | 14% |
| Ceftriaxone | 21% | 38% | 6% | 22% |
| Cefuroxime | 15% | 16% | 10% | 14% |
| Ciprofloxacillin | 7% | 13% | 41% | 20% |
| Bactrim | 7% | 5% | 52% | 18% |
| Ceftazidime | 7% | 33% | 3% | 13% |
| Metronidazole | 6% | 8% | 5% | 13% |
| Piperacillin/tazobactam | 6% | 31% | 3% | 11% |
| Meropenem | 4% | 12% | 2% | 5% |
| Amikacin | 3% | 9% | 4% | 5% |